Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

COVID-19: The Unprecedented Malady- A Holistic Review

Author(s): Viney Chawla and Pooja A. Chawla*

Volume 2, Issue 2, 2021

Published on: 13 August, 2020

Page: [172 - 181] Pages: 10

DOI: 10.2174/2666796701999200813191218

Price: $65

Abstract

Background: Coronavirus disease (COVID-19) is spreading rapidly at an unprecedented scale across continents and has emerged as the single biggest risk the world has faced in modern times. Some scientists are comparing it to Spanish flu that created havoc around a century ago. The fear of death by COVID-19 looms large in the world today. The disease has reached devastating proportions since its first reports in December 2019. Doctors are having a difficult time dealing with this challenge and the microbiologists are having sleepless nights to bring about an effective vaccine for this disease. Methods: A number of research and review articles have been exhaustively reviewed. The collected data has been meticulously analyzed and documented.

Conclusion: This paper reviews the different types of coronaviruses, the structure of SARS-CoV-2 responsible for COVID-19, its transmission, and virulence. Further, the article discusses the diagnosis, signs and symptoms like fever, breathlessness, cough, potential loss of taste or smell, sneezing, runny nose, fatigue, headache, sore throat and different treatment approaches including drug repurposing being tried by doctors around the globe that may come handy in the management of disease symptoms. The article describes the use of remdesivir, ribavarin, lopinavir, favipiravir, hydoxychloroquine, chloroquine, and tocilizumab among others in treating COVID-19.

Keywords: Coronavirus disease, COVID-19, chloroquine, diagnosis, SARS CoV-2 structure, pandemic, drug repurposing.

[1]
World Health Organization. Coronavirus disease (COVID-19) pandemic. Available from: http://www.who.int/emergencies/diseases/novel-coronavirus-2019/ (Accessed 16 April, 2020).
[2]
Worldometer. COVID-19 Coronavirus Pandemic. Available from: http://www.worldometers.info/coronavirus/ (Accessed 16 April, 2020).
[3]
Chung M, Bernheim A, Mei X, et al. CT Imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020; 295: 685-91.
[http://dx.doi.org/doi:10.1148/radiol.2020200230]
[4]
Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20: 660-94.
[http://dx.doi.org/doi.org/10.1128/CMR.00023-07]
[5]
To KK, Hung IF, Chan JF, Yuen KY. From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis 2013; 5(Suppl. 2): S103-8.
[http://dx.doi.org/doi.org/10.3978/j.issn.2072-1439.2013.06.02]
[6]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/doi.org/10.1001/jama.2020.2648]
[7]
Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011; 81: 85-164.
[http://dx.doi.org/doi.org/10.1016/B978-0-12-385885-6.00009-2]
[8]
Masters PS, Perlman S. Coronaviridae.Knipe DM, Howley PM. Eds Fields virology. 6th ed. Lippincott Williams and Wilkins 2013; pp. 825-58.
[9]
Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24: 490-502.
[http://dx.doi.org/doi.org/10.1016/j.tim.2016.03.003]
[10]
Le-Viet N, Le VN, Chung H, et al. Prospective case–control analysis of the aetiologies of acute undifferentiated fever in Vietnam. Emerg Microbes Infect 2019; 8: 339-52.
[http://dx.doi.org/doi.org/10.1080/22221751.2019.1580539]
[11]
Hand J, Rose EB, Salinas A, et al. Severe respiratory illness outbreak associated with human coronavirus NL63 in a long-term care facility. Emerg Infect Dis 2018; 24: 1964-6.
[http://dx.doi.org/doi.org/10.3201/eid2410.180862]
[12]
Vandroux D, Allou N, Jabot J, et al. Intensive care admission for coronavirus OC43 respiratory tract infections. Med Mal Infect 2018; 48: 141-4.
[http://dx.doi.org/doi.org/10.1016/j.medmal.2018.01.001]
[13]
Kanwar A, Selvaraju S, Esper F. Human coronavirus-HKU1 infection among adults in Cleveland, Ohio. Open Forum Infect Dis 2017; 4(2)ofx052
[http://dx.doi.org/doi.org/10.1093/ofid/ofx052]
[14]
Trombetta H, Faggion HZ, Leotte J, Nogueira MB, Vidal LR, Raboni SM. Human coronavirus and severe acute respiratory infection in Southern Brazil. Pathog Glob Health 2016; 110: 113-8.
[http://dx.doi.org/doi.org/10.1080/20477724.2016.1181294]
[15]
Lau SK, Woo PC, Yip CC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol 2006; 44: 2063-71.
[http://dx.doi.org/doi.org/10.1128/JCM.02614-05]
[16]
Owusu M, Annan A, Corman VM, et al. Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana. PLoS One 2014; 9e99782
[http://dx.doi.org/doi.org/10.1371/journal.pone.0099782]
[17]
Zhang SF, Tuo JL, Huang XB, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. PLoS One 2018; 13e0191789
[http://dx.doi.org/doi.org/10.1371/journal.pone.0191789]
[18]
Zeng ZQ, Chen DH, Tan WP, et al. Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China. Eur J Clin Microbiol Infect Dis 2018; 37: 363-9.
[http://dx.doi.org/doi.org/10.1007/s10096-017-3144-z]
[19]
Kiyuka PK, Agoti CN, Munywoki PK, et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J Infect Dis 2018; 217: 1728-39.
[http://dx.doi.org/doi.org/10.1093/infdis/jiy098]
[20]
Killerby ME, Biggs HM, Haynes A, et al. Human coronavirus circulation in the United States 2014–2017. J Clin Virol 2018; 101: 52-6.
[http://dx.doi.org/doi.org/10.1016/j.jcv.2018.01.019]
[21]
Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet 2003; 362: 1353-8.
[http://dx.doi.org/doi.org/10.1016/s0140-6736(03)14630-2]
[22]
Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953-66.
[http://dx.doi.org/doi.org/10.1056/NEJMoa030781]
[23]
Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967-76.
[http://dx.doi.org/doi.org/10.1056/NEJMoa030747]
[24]
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814-20.
[http://dx.doi.org/doi.org/10.1056/NEJMoa1211721]
[25]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17: 181-92.
[http://dx.doi.org/doi.org/10.1038/s41579-018-0118-9]
[26]
Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao GF. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe 2015; 18: 398-401.
[http://dx.doi.org/doi.org/10.1016/j.chom.2015.09.013]
[27]
Woo PC, Lau SK, Lam CS, et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 2012; 86: 3995-4008.
[http://dx.doi.org/doi.org/10.1128/JVI.06540-11]
[28]
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.
[http://dx.doi.org/doi.org/10.1056/NEJMoa2001017]
[29]
Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagnos Interven Imag 2020; 101(5): 263-8.
[http://dx.doi.org/doi.org/10.1016/j.diii.2020.03.014]
[30]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207.
[http://dx.doi.org/doi.org/10.1056/NEJMoa2001316]
[31]
Goldsmith CS, Tatti KM, Ksiazek TG, et al. Ultrastructural characterization of SARS coronavirus. Emerg Infect Dis 2004; 10: 320-6.
[http://dx.doi.org/doi.org/10.3201/eid1002.030913]
[32]
Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69: 635-64.
[http://dx.doi.org/doi.org/10.1128/MMBR.69.4.635-664.2005]
[33]
Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 1997; 48: 1-100.
[http://dx.doi.org/doi.org/10.1016/S0065-3527(08)60286-9]
[34]
de Groot RJ, Baker SC, Baric R, et al. Family Coronaviridae.International committee on taxonomy of viruses, international union of microbiological societies. Virology division In: 9th report of the international committee on taxonomy of viruses Oxford: Elsevier pp. 806-28.
[35]
Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH. The SARS coronavirus nucleocapsid protein--forms and functions. Antiviral Res 2014; 103: 39-50.
[http://dx.doi.org/doi.org/10.1016/j.antiviral.2013.12.009]
[36]
Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Str Bio 2011; 174: 11-22.
[http://dx.doi.org/doi.org/10.1016/j.jsb.2010.11.021]
[37]
Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res 2013; 100: 605-14.
[http://dx.doi.org/doi.org/10.1016/j.antiviral.2013.09.028]
[38]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis; attachment and entry.Maier HJ, Bickerton E, Britton P. ,Eds Coronaviruses: methods and protocols, methods in molecular biology New York: Humana Press, pp. 1-23.
[http://dx.doi.org/doi.org/10.1007/978-1-4939-2438-7_1]
[39]
Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. Homology-based identification of a mutation in the Coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 2016; 90: 7415-28.
[http://dx.doi.org/doi.org/10.1128/JVI.00080-16]
[40]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 180: 1-12.
[http://dx.doi.org/doi.org/10.1016/j.cell.2020.02.058]
[41]
Centers for Disease Control and Prevention. Transmission of Novel Coronavirus (2019-nCoV). Available from: www.cdc.gov (Assessed 27 March 2020)
[42]
Wang G, Deering C, Macke M, et al. Human coronavirus 229E infects polarized airway epithelia from the apical surface. J Virol 2000; 74: 9234-9.
[http://dx.doi.org/doi.org/10.1128/jvi.74.19.9234-9239.2000]
[43]
Pyrc K, Sims AC, Dijkman R, et al. Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J Virol 2010; 84: 11255-63.
[http://dx.doi.org/doi.org/10.1128/JVI.00947-10]
[44]
Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of Coronavirus disease (COVID-19): encephalopathy. Cureus 2020; 12e7352
[http://dx.doi.org/doi.org/10.7759/cureus.7352]
[45]
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683-90.
[http://dx.doi.org/doi:10.1001/jamaneurol.2020.1127]
[46]
Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020; 94: 55-8.
[http://dx.doi.org/doi:10.1016/j.ijid.2020.03.062]
[47]
Vollono C, Rollo E, Romozzi M, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure 2020; 78: 109-12.
[http://dx.doi.org/doi:10.1016/j.seizure.2020.04.009]
[48]
Guan GW, Gao L, Wang JW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Chin J Hepat 2020; 28E002
[http://dx.doi.org/doi.org/10.3760/cma.j.issn.1007-3418.2020.02.002]
[49]
Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158(6): 1831-3.
[http://dx.doi.org/doi.org/10.1053/j.gastro.2020.02.055]
[50]
Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55-63.
[http://dx.doi.org/doi.org/10.1038/nrmicro.2016.142]
[51]
He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut-lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol 2017; 43: 81-95.
[http://dx.doi.org/doi.org/10.1080/1040841X.2016.1176988]
[52]
Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China. Zhonghua Er Ke Za Zhi 2020; 58e005
[http://dx.doi.org/doi.org/10.3760/cma.j.issn.0578-1310.2020.0005]
[53]
Tang A, Tong ZD, Wang HL, et al. Detection of Novel Coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis 2020; 26(6): 1.
[http://dx.doi.org/doi.org/10.3201/eid2606.200301]
[54]
Xie C, Jiang L, Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis 2020; 93: 264-7.
[http://dx.doi.org/doi.org/10.1016/j.ijid.2020.02.050]
[55]
Li M, Wang B, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117-22.
[http://dx.doi.org/doi.org/10.1073/pnas.0712038105]
[56]
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-7.
[http://dx.doi.org/doi:10.1016/j.thromres.2020.04.013]
[57]
Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020; 18(6): 1517-9.
[http://dx.doi.org/doi.org/10.1111/jth.14844.]
[58]
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76: 16-32.
[http://dx.doi.org/doi.org/10.1128/MMBR.05015-11]
[59]
Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020; 27(3)taaa041
[http://dx.doi.org/10.1093/jtm/taaa041]
[60]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9.
[http://dx.doi.org/doi:10.1001/jama.2020.1585]
[61]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395: 497-506.
[http://dx.doi.org/doi.org/10.1016/S0140-6736(20)30183-5]
[62]
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5(7): 802-10.
[http://dx.doi.org/doi:10.1001/jamacardio.2020.0950]
[63]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 54-62.
[http://dx.doi.org/doi:10.1016/S0140-6736(20)30566-3]
[64]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med 2020; 382: 1708-20.
[http://dx.doi.org/doi.org/10.1056/NEJMoa2002032]
[65]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395: 507-13.
[http://dx.doi.org/doi.org/10.1016/S0140-6736(20)30211-7]
[66]
Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? The Lancet Gastroenterol Hepatol 2020; 5: 335-7.
[http://dx.doi.org/doi.org/10.1016/S2468-1253(20)30048-0]
[67]
Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005; 67: 698-705.
[http://dx.doi.org/doi.org/10.1111/j.1523-1755.2005.67130.x]
[68]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island: StatPearls Publishing 2020.
[69]
Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus 2020; 12e7355
[http://dx.doi.org/doi.org/10.7759/cureus.7355]
[70]
Kooraki S, Hosseiny M, Myers L, Gholamrezanezhad A. Coronavirus (COVID-19) outbreak: what the department of radiology should know. J Am Coll Radiol 2020; 17(4): 447-51.
[http://dx.doi.org/doi.org/10.1016/j.jacr.2020.02.008]
[71]
Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta 2020; 505: 190-1.
[http://dx.doi.org/doi.org/10.1016/j.cca.2020.03.004]
[72]
Indian Institute of Technology Delhi. Available from: www.iitdelhi.ac.in/research (Accessed 28 March 2020)
[73]
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 17105924
[http://dx.doi.org/doi.org/10.1016/j.ijantimicag.2020.105924]
[74]
Lombardi A, Bozzi G, Mangioni D, et al. Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer. J Hosp Infect 2020; 105(3): 404-5.
[http://dx.doi.org/doi.org/10.1016/j.jhin.2020.03.003]
[75]
da Silva MR, Schapochnik A, Leal MP, et al. Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat. PLoS One 2018; 13e0205535
[http://dx.doi.org/doi.org/10.1371/journal.pone.0205535]
[76]
Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583.
[http://dx.doi.org/doi.org/10.1136/bmj.i6583]
[77]
Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381-5.
[http://dx.doi.org/doi.org/10.1038/nature17180]
[78]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: 396.
[http://dx.doi.org/doi.org/10.1126/scitranslmed.aal3653]
[79]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med 2020; 382: 2327-36.
[http://dx.doi.org/doi.org/10.1056/NEJMoa2007016]
[80]
Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020; 21(5): 730-8.
[http://dx.doi.org/doi.org/10.1002/cbic.202000047]
[81]
Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f] [triazin-4-amino] adenine c-nucleoside (GS-5734) for the treatment of Ebola and emerging Viruses. J Med Chem 2017; 60(5): 1648-61.
[http://dx.doi.org/doi.org/10.1021/acs.jmedchem.6b01594]
[82]
Ko WC, Rolain JM, Lee NY, et al. Arguments in favor of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020; 2020105933
[http://dx.doi.org/doi.org/10.1016/j.ijantimicag.2020.105933]
[83]
Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993; 57: 203-35.
[http://dx.doi.org/doi.org/10.1016/0163-7258(93)90056-j]
[84]
Tsiang H, Superti F. Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Arch Virol 1984; 81: 377-82.
[http://dx.doi.org/doi/10.1007/bf01310010]
[85]
Kronenberger P, Vrijsen R, Boeyé A. Chloroquine induces empty capsid formation during poliovirus eclipse. J Virol 1991; 65: 7008-11.
[http://dx.doi.org/doi/10.1128/JVI.65.12.7008-7011.1991]
[86]
Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 2001; 20: 137-40.
[http://dx.doi.org/doi.org/10.1016/s1386-6532(00)00140-2]
[87]
Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990; 6: 481-9.
[http://dx.doi.org/doi.org/10.1089/aid.1990.6.481]
[88]
Romanelli F, Smith KM, Hoven AD. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharm Des 2004; 10: 2643-8.
[http://dx.doi.org/doi.org/10.2174/1381612043383791]
[89]
Superti F, Seganti L, Orsi W, Divizia M, Gabrieli R, Pana A. The effect of lipophilic amines on the growth of hepatitis A virus in Frp/3 cells. Arch Virol 1987; 96: 289-96.
[http://dx.doi.org/doi.org/10.1007/bf01320970]
[90]
Bishop NE. Practical guidelines in antiviral therapy. Intervirology 1998; 41: 261-71.
[91]
Mizui T, Yamashina S, Tanida I, et al. Inhibition of hepatitis C virus replication by chloroquine targeting virusassociated autophagy. J Gastroenterol 2010; 45: 195-203.
[http://dx.doi.org/doi.org/10.1007/s00535-009-0132-9]
[92]
Miller DK, Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci USA 1981; 78: 3605-9.
[http://dx.doi.org/doi.org/10.1073/pnas.78.6.3605]
[93]
Shibata M, Aoki H, Tsurumi T, et al. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol 1983; 64: 1149-56.
[http://dx.doi.org/doi.org/10.1099/0022-1317-64-5-1149]
[94]
Ooi EE, Chew JS, Loh JP, Chua RC. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006; 3: 39.
[http://dx.doi.org/doi.org/10.1186/1743-422X-3-39]
[95]
Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011; 11: 677-83.
[http://dx.doi.org/doi.org/10.1016/S1473-3099(11)70065-2]
[96]
Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013; 23: 300-2.
[http://dx.doi.org/doi.org/10.1038/cr.2012.165]
[97]
De Lamballerie X, Boisson V, Reynier JC, et al. On Chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008; 8: 837-40.
[http://dx.doi.org/doi.org/10.1089/vbz.2008.0049]
[98]
Khan M, Santhosh SR, Tiwari M, Lakshmana Rao PV, Parida M. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells. J Med Virol 2010; 82: 817-24.
[http://dx.doi.org/doi.org/10.1002/jmv.21663]
[99]
Delogu I, de Lamballerie X. Chikungunya disease and chloroquine treatment. J Med Virol 2011; 83: 1058-9.
[http://dx.doi.org/doi.org/10.1002/jmv.22019]
[100]
Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990; 174: 450-8.
[http://dx.doi.org/doi.org/10.1016/0042-6822(90)90099-d]
[101]
Farias KJ, Machado PR, de Almeida Junior RF, de Aquino AA, da Fonseca BA. Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol 2014; 58: 318-26.
[http://dx.doi.org/doi.org/10.1111/1348-0421.12154]
[102]
Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses 2016; 8e322
[http://dx.doi.org/doi.org/10.3390/v8120322]
[103]
Glushakova SE, Lukashevich IS. Early events in arenavirus replication are sensitive to lysosomotropic compounds. Arch Virol 1989; 104: 157-61.
[http://dx.doi.org/doi.org/10.1007/bf01313817]
[104]
Porotto M, Orefice G, Yokoyama CC, et al. Simulating Henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol 2009; 83: 5148-55.
[http://dx.doi.org/doi.org/10.1128/JVI.00164-09]
[105]
Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 2010; 91: 765-72.
[http://dx.doi.org/doi.org/10.1099/vir.0.017269-0]
[106]
Ferraris O, Moroso M, Pernet O, et al. Evaluation of Crimean–Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. Antiviral Res 2015; 118: 75-81.
[http://dx.doi.org/doi.org/10.1016/j.antiviral.2015.03.005]
[107]
Dowall SD, Bosworth A, Watson R, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol 2015; 96: 3484-92.
[http://dx.doi.org/doi.org/10.1099/jgv.0.000309]
[108]
Kouroumalis EA, Koskinas J. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann Acad Med Singapore 1986; 15: 149-52.
[109]
Koyama AH, Uchida T. Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine. Virology 1984; 138: 332-5.
[http://dx.doi.org/doi.org/10.1016/0042-6822(84)90356-8]
[110]
White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet 2014; 383: 723-35.
[http://dx.doi.org/doi.org/10.1016/S0140-6736(13)60024-0]
[111]
Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinine oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004; 43: 4538-47.
[http://dx.doi.org/doi.org/10.1021/bi035923w]
[112]
Varki A. Sialic acids as ligands in recognition phenomena. FASEB J 1997; 11: 248-55.
[http://dx.doi.org/doi.org/10.1096/fasebj.11.4.9068613]
[113]
Olofsson S, Kumlin U, Dimock K, Arnberg N. Avian influenza and sialic acid receptors: more than meets the eye? Lancet Infect Dis 2005; 5: 184-8.
[http://dx.doi.org/doi.org/10.1016/S1473-3099(05)01311-3]
[114]
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69.
[http://dx.doi.org/doi.org/10.1186/1743-422X-2-69]
[115]
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55105938
[http://dx.doi.org/doi.org/10.1016/j.ijantimicag.2020.105938]
[116]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents 2020; 56105949
[http://dx.doi.org/doi.org/10.1016/j.ijantimicag.2020.105949]
[117]
Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): facts and myths. J Microbiol Immunol Infect 2020; S1684-1182(20): 30040-2.
[http://dx.doi.org/10.1016/j.jmii.2020.02.012]
[118]
Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-6.
[http://dx.doi.org/doi.org/10.1136/thorax.2003.012658]
[119]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14: 58-60.
[http://dx.doi.org/doi.org/10.5582/ddt.2020.01012]
[120]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19: 149-50.
[http://dx.doi.org/doi.org/10.1038/d41573-020-00016-0]
[121]
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020; 14: 69-71.
[http://dx.doi.org/doi.org/10.5582/bst.2020.01020]
[122]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178104787
[http://dx.doi.org/doi.org/10.1016/j.antiviral.2020.104787]
[123]
Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res 2020; 177104760
[http://dx.doi.org/doi.org/10.1016/j.antiviral.2020.104760]
[124]
Zhang J, Ma X, Yu F, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv 2020; 2020: 1.
[http://dx.doi.org/doi.org/10.1101/2020.02.05.935387]
[125]
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents 2020; 55(4)105944
[126]
The Hindu. Anti-HIV drugs given to COVID-19-affected Italian couple in Jaipur Available from: http://www.thehindu.com/news/national/other-states/anti-hiv-drugs-given-to-covid-19-affected-italian-couple-in-jaipur/article31033762.ece/

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy